LabCorp ($LH) and China's Fosun Pharma are among the investors in a $15 billion Series B round that funds Ativa Medical's point-of-care diagnostics technology. Other participants in the round include Diamond BioFund, Taiwan's largest healthcare fund, and China's Dian Diagnostics, a diagnostics services provider. Ativa says its analyzer can perform many common tests within 5 minutes using a few drops of blood. More from FierceMedicalDevices